98%
921
2 minutes
20
Introduction: Hospital-acquired infections (HAIs) caused by bacterial and viral pathogens continue to affect millions annually, placing a persistent burden on healthcare systems. Traditional infection control strategies often fall short due to their inability to assess real-time spatial and movement data within healthcare environments dynamically. This study addresses that gap by leveraging the concept of (CP), a behavior- and context-driven metric of infection risk, to develop a framework for minimizing the incidence of HAIs.
Methods: The proposed framework integrates CP, which encapsulates an individual's susceptibility and transmissibility, taking into account movement patterns and interactions across hospital units. Unlike models requiring precise tracking, this approach uses coarse location data to construct a dynamic infection risk landscape. CP parameters are continuously learned and updated over time through behavioral data, enabling real-time risk inference. The framework also introduces a CP-based optimization algorithm for patient-to-unit assignments that jointly minimizes contagion risk while satisfying clinical and logistical constraints.
Results: The framework's efficacy is validated through modular and integrated evaluations. Simulations incorporate mobility patterns reflecting homogeneous and heterogeneous mixing, with infection spread following empirically grounded transmission models. Results demonstrate that incorporating CP significantly reduces infection propagation, enhances patient safety, and leads to more efficient healthcare resource allocation.
Discussion: This study presents a dynamic, data-driven framework for infection control within healthcare facilities. By incorporating behavior-aware contagion metrics into patient flow decisions, the approach offers a scalable and proactive infection prevention strategy. The findings underscore the potential of CP to improve both operational outcomes and patient well-being in healthcare environments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350498 | PMC |
http://dx.doi.org/10.3389/fpubh.2025.1566854 | DOI Listing |
Int J Epidemiol
August 2025
Department of Biostatistics and Informatics, University of Colorado, Aurora, CO, United States.
Background: Existing longitudinal cohort study data and associated biospecimen libraries provide abundant opportunities to efficiently examine new hypotheses through retrospective specimen testing. Outcome-dependent sampling (ODS) methods offer a powerful alternative to random sampling when testing all available specimens is not feasible or biospecimen preservation is desired. For repeated binary outcomes, a common ODS approach is to extend the case-control framework to the longitudinal setting.
View Article and Find Full Text PDFEur J Gastroenterol Hepatol
August 2025
Department of Medical and Surgical Sciences, University of Bologna.
Background: Gastric cancer epidemiology evolved rapidly in the last century, shifting from being one of the main causes of cancer-related death to the sixth in high-income countries.
Methods: We conducted a narrative review on gastric cancer epidemiology. Our review focused on trends of gastric cancer and its relationship with Helicobacter pylori infection; cardia and noncardia gastric cancer risk factors; early onset gastric cancer; second primary cancers in patients with gastric cancer; and implementation of gastric cancer prevention strategies.
N Engl J Med
September 2025
Rwanda Biomedical Center, Kigali.
Background: On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals.
Methods: We report key aspects of the epidemiology, clinical manifestations, and treatment of MVD during this outbreak, as well as the overall response to the outbreak. We performed a retrospective epidemiologic and clinical analysis of data compiled across all pillars of the outbreak response and a case-series analysis to characterize clinical features, disease progression, and outcomes among patients who received supportive care and investigational therapeutic agents.
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Epidemiol Serv Saude
September 2025
Instituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, PE, Brazil.
Objective: To estimate the incidence and factors associated with SARS-CoV-2 reinfection and post-vaccination infection in nursing professionals.
Methods: This was a prospective, descriptive, and analytical cohort study conducted in Recife from March 2020 to January 2023, following 399 nursing professionals. The cumulative incidences of COVID-19 infection and reinfection were estimated with a 95% confidence interval (95%CI).